On September 3, 2024, Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, announced the successful closing of a $90 million Series D financing round, which includes the conversion of a convertible note. The financing was led by The Column Group with participation from new and existing investors, including Nextech Invest and Euclidean Capital. The proceeds from the financing will be used to fund the clinical development of CID-078, Circle Pharma’s first-and-only-in-class cyclin A/B RxL inhibitor, and to support the development of the company’s portfolio of discovery programs built with its MXMO macrocycle platform.

Wilson Sonsini Goodrich & Rosati represented Circle Pharma in the transaction. The Wilson Sonsini team includes Elton Satusky, Jesse Schumaker, and Davelyn Bulovas.

For more information, please see Circle Pharma’s press release.